



UK Health
Security
Agency

National Influenza and COVID-19 surveillance report

Week 44 report (up to week 43 data)

2 November 2023

Contents

Executive summary	4
Laboratory surveillance	6
Respiratory DataMart system (England).....	6
Confirmed COVID-19 cases (England).....	12
Microbiological surveillance	15
SARS-CoV-2 variants	15
Influenza virus characterisation	18
Influenza antiviral susceptibility	19
Community surveillance	20
Acute respiratory infection incidents	20
Google search queries	23
Flu Detector	24
Syndromic surveillance.....	25
Primary care surveillance	29
RCGP Clinical Indicators (England).....	29
RCGP sentinel swabbing scheme in England	30
Secondary care surveillance	34
Influenza, SARI Watch	34
COVID-19, SARI Watch	41
ECMO, SARI Watch	46
RSV admissions, SARI Watch.....	47
Mortality surveillance	50
COVID-19 deaths	50
Daily excess all-cause mortality (England)	50
Influenza vaccination	51
Influenza vaccine uptake in GP patients.....	51
COVID-19 vaccination.....	53
COVID-19 vaccine uptake in England	53
International update	58

Global COVID-19 update..... 58

Global influenza update..... 58

Other respiratory viruses 58

Related links 59

For additional information including regional data on COVID-19 and other respiratory viruses, COVID-19 in educational settings, co- and secondary infections with COVID-19 and other data supplementary to this report, please refer to the [accompanying graph pack](#).

For additional information regarding data source please refer to [Sources of surveillance data for influenza, COVID-19 and other respiratory viruses](#).

Executive summary

This report summarises the information from the surveillance systems which are used to monitor COVID-19 (causing by SARS-CoV-2), influenza, and diseases caused by seasonal respiratory viruses in England. References to COVID-19 represent the disease name and SARS-CoV-2 represent the virus name. The report is based on data from week 43 (between 23 October and 29 October 2023).

Overall

In week 43, influenza activity remained stable across most indicators. COVID-19 activity showed a decrease of activity across almost all indicators. RSV activity continued to rise in all indicators, driven by marked increases in children.

Influenza

Through Respiratory DataMart, influenza positivity remained stable at 1.3% in week 43 compared to 1.2% in the previous week.

Through primary care surveillance, the influenza-like-illness (ILI) consultations indicator decreased slightly to 3.2 per 100,000 in week 43 compared to 3.5 per 100,000 the previous week and was within the baseline activity level range.

There were no influenza confirmed outbreaks reported in England in week 43.

Overall, influenza hospitalisations remained at baseline activity in week 43. Influenza intensive care unit (ICU) or high dependency unit (HDU) admissions remained at baseline activity compared to the previous week. There were two influenza ICU or HDU admissions in week 43.

Emergency department (ED) attendances for ILI remained stable nationally.

Influenza vaccine uptake for the 2023 to 2024 influenza season is reported for the fourth time. Compared to the equivalent week in the 2022 to 2023 season, vaccine uptake remains higher for those aged 65 years and over, pregnant women and 2 and 3 year olds; and is comparable for those under 65 years in clinical risk groups.

COVID-19

Through Respiratory DataMart, SARS-CoV-2 positivity decreased to 8.7% in week 43 compared to 9.7% in the previous week.

COVID-19 case rates and positivity rates through Pillar 1 decreased in most age groups, regions and most ethnic groups in week 43.

The overall number of reported SARS-CoV-2 confirmed outbreaks remained stable compared to the previous week. There were 8 SARS-CoV-2 confirmed outbreaks reported in week 43 in England.

Overall, COVID-19 hospitalisations decreased to 4.04 per 100,000 in week 43 compared to 4.57 per 100,000 in the previous week. Hospitalisations were highest in the 85 years and over age group. COVID-19 ICU admissions remained low and stable in week 43 compared to the previous week.

Through syndromic surveillance indicators, ED attendances for COVID-like illness continued to decrease nationally.

RSV

The overall positivity for respiratory syncytial virus (RSV) increased slightly to 8.7%, with the highest positivity in those aged under 5 years old at 34.1%. ED attendances for acute bronchiolitis continued to increase nationally, as well as hospital admission rates.

Other viruses

Adenovirus positivity increased to 2.7%, with the highest positivity in children under 5 years old at 6.9%. Human metapneumovirus (hMPV) positivity remained low at 1.0%, with the highest positivity in children under 5 years old at 3.2%. Parainfluenza positivity remained low at 0.9%, with the highest positivity in children under 5 years old at 1.8%. Rhinovirus positivity decreased to 15.4% overall, with the highest positivity in children under 5 years old at 25.3%.

Laboratory surveillance

Respiratory DataMart system (England)

In week 43, data is based on reporting from 12 out of the 16 sentinel laboratories.

In week 43, 5,230 respiratory specimens reported through the Respiratory DataMart System were tested for influenza. 72 samples tested positive for influenza; 35 influenza A(not subtyped), 21 influenza A(H3N2), 15 were influenza B and one influenza A(H1N1)pdm09 (Figure 4). Overall, influenza positivity remained stable at 1.3% in week 43 compared to 1.2% in the previous week.

In week 43, 5,350 respiratory specimens reported through the Respiratory DataMart System were tested for SARS-CoV-2. 469 samples were positive for SARS-CoV-2 with an overall positivity of 8.7%, which decreased compared to 9.7% in the previous week. The highest positivity was seen in adults aged over 65 years at 10.9%.

Adenovirus positivity increased to 2.7%, with the highest positivity in children under 5 years old at 6.9%.

Human metapneumovirus (hMPV) positivity remained low at 1.0%, with the highest positivity in children under 5 years old at 3.2%.

Parainfluenza positivity remained low at 0.9%, with the highest positivity in children under 5 years old at 1.8%.

Rhinovirus positivity decreased to 15.4% overall, with the highest positivity in children under 5 years old at 25.3%.

The overall positivity for RSV increased to 8.7%, with the highest positivity in those aged under 5 years old at 34.1%.

Figure 1: Respiratory DataMart weekly positivity (%) for a) influenza, SARS-CoV-2, RSV and rhinovirus and b) adenovirus, hMPV and parainfluenza, England





Figure 2: Respiratory DataMart weekly positivity (%) for influenza by year, England



Please note data from seasons 2020 to 2021 and 2021 to 2022 has been removed as there was low activity throughout these seasons.

Figure 3: Respiratory DataMart samples positive for influenza by type and subtype, England




Figure 4: Respiratory DataMart weekly positivity (%) for influenza by age, England




Figure 5: Respiratory DataMart weekly positivity (%) for SARS-CoV-2 by year, England




Figure 6: Respiratory DataMart weekly positivity (%) for SARS-CoV-2 by age, England




Figure 7: Respiratory DataMart weekly positivity (%) for RSV by year, England





Figure 8: Respiratory DataMart weekly positivity (%) for RSV by age, England




Confirmed COVID-19 cases (England)

As of 9am on 23 October 2023, a total of 2,148,553 episodes have been confirmed for COVID-19 in England under Pillar 1, and 18,844,726 episodes under Pillar 2, since the beginning of the pandemic. COVID-19 case rates through Pillar 1 decreased in week 43.

Data notes: Changes to testing policies over time may affect positivity rates and incidence rates and should be interpreted accordingly. COVID-19 case reporting in England uses an episode-based definition which includes possible reinfections, each infection episode is counted separately if there are at least 91 days between positive test results (polymerase chain reaction (PCR) or rapid lateral flow device). Each infection episode begins with the earliest positive specimen date. Additionally, further changes in [testing policy](#) are in effect since 1 April 2023, which may affect case rates and positivity rates.


Figure 9: Confirmed COVID-19 episodes tested under Pillar 1, based on sample date with overall seven-day rolling average PCR positivity for Pillar 1 (%)



The vertical dashed line (red) denotes changes in testing policies.

Age


Figure 10: Seven-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 1 by age group



Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.

Geography


Figure 11: Seven-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 1 by UKHSA region



Please note the highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.

Ethnicity

Figure 12: Weekly incidence of confirmed COVID-19 cases per 100,000 population by ethnicity (Pillar 1), England



Please note the highlighted line corresponds to the ethnicity in the subplot title, grey lines correspond to all other ethnicities

Microbiological surveillance

SARS-CoV-2 variants

This section is updated fortnightly with updated data presented in this report. There is no update for this week.

UK Health Security Agency (UKHSA) conducts genomic surveillance of SARS-CoV-2 variants.

This section provides an overview of new and current circulating variants in England.

Detailed surveillance of particular variants of concerns can be found in recent [technical briefings](#).


Information on whole genome sequencing coverage can be found in the accompanying slide set.

The prevalence of different UKHSA-designated variants amongst sequenced episodes is presented in Figure 13.

Variants may include many sub-lineages that have not been individually designated for example XBB.1.9.2 within XBB (V-22OCT-02). As a result, prevalence of that variant appears to be increasing as a whole, masking the effect of one or more growing sub-lineages. Once a sub-lineage meets required thresholds to be declared a variant, it will be designated as a variant and prevalence of this sub-lineage in positive cases will then be identifiable in the data.

To account for sequencing delays, we report the proportion of variants from sequenced episodes between 9 October 2023 and 15 October 2023. Of those sequenced in this period, 33.2% were classified as EG.5.1 (V-23JUL-01), 25.9% as XBB (V-22OCT-02), 24.6% as XBB.1.16 (V-23APR-01), 9.1% as XBB.1.5 (V-23JAN-01), 4.3% as BA.2.86 (V-23AUG-01) and 2.5% as CH.1.1 (V-22DEC-01).

Figure 13: Prevalence of SARS-CoV-2 variants amongst available sequences episodes for England from 24 October 2022 to 22 October 2023



The grey line indicates proportion of cases sequenced.

The vertical dashed line (red) denotes changes in testing policy with regards to PCR testing in social care and hospital settings.

Note: Recombinants such as XD are not specified but are largely within the 'Other' group currently as numbers are too small.

Table 1. Total distribution of SARS-CoV-2 variants detected in England in the last 12 weeks, up to week 43 (week ending 22 October 2023)

Variant	Other names by which this variant is known	Total confirmed (sequencing) cases in the last 12 weeks	Last reported specimen date
VOC-21NOV-01	Omicron BA.1	1	05-10-2023
V-22JAN-01	Omicron BA.2	33	16-10-2023
V-22APR-04	Omicron BA.5	7	06-10-2023
V-22JUL-01	Omicron BA.2.75	1	25-08-2023
V-22OCT-01	Omicron BQ.1	18	12-10-2023
V-22OCT-02	Omicron XBB	3303	18-10-2023
V-22DEC-01	Omicron CH.1.1	243	17-10-2023
V-23JAN-01	Omicron XBB.1.5	835	17-10-2023
V-23APR-01	Omicron XBB.1.16	3321	18-10-2023
V-23JUL-01	Omicron EG.5.1	3781	18-10-2023
V-23AUG-01	Omicron BA.2.86	237	17-10-2023

Sequencing data has a lag of approximately two weeks therefore the data presented should be interpreted in this context.

Cumulative numbers may be revised up or down as a result of reclassification, re-infections and changes to diagnostic tests, new variants or public health management levels.

Confirmed individuals are confirmed COVID-19 cases with a validated sequencing result meeting the confirmed case definition.

Influenza virus characterisation

UKHSA characterises the properties of influenza viruses through one or more tests, including genome sequencing (genetic analysis) and haemagglutination inhibition (HI) assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses as the viruses which can be recovered and analysed antigenically may not be fully representative of majority variants, and genetic characterisation data does not always predict the antigenic characterisation.

As of week 43 (ending 29 October 2023), the UKHSA Respiratory Virus Unit (RVU) has genetically characterised 18 influenza A(H3N2) viruses, which were detected since week 34. Sequencing of the haemagglutinin (HA) gene shows that these A(H3N2) viruses belong in genetic subclade 3C.2a1b.2a.2 in the 2a.3a.1 subgroup. The Northern Hemisphere 2023/24 influenza A(H3N2) vaccine strain (an A/Darwin/9/2021-like virus) also belongs in genetic subclade 3C.2a1b.2a.2.

Thirteen influenza A(H1N1)pdm09 viruses have been characterised to date this season, with eight belonging in genetic subgroup 6B.1A.5a.2a and five in subgroup 6B.1A.5a.2a.1. The Northern Hemisphere 2023/24 influenza A(H1N1)pdm09 vaccine strain (an A/Victoria/4897/2022 (H1N1)pdm09-like virus) also belongs in genetic subclade 6B.1A.5a, within the 6B.1A.5a.2a.1 cluster.

One influenza B/Victoria lineage virus has been genetically characterised belonging in subclade V1A3, within the subgroup V1A3a.2. The Northern Hemisphere 2023/24 influenza B/Victoria lineage vaccine strain (a B/Austria/1359417/2021-like virus) also belongs in this V1A3a.2 subclade/group.

At this early stage of the influenza season, it is too early to predict which influenza lineages will dominate throughout the season, and a close watch will be kept on the proportion of different viruses circulating to assist with the evaluation of vaccine effectiveness.

The RVU has confirmed by genome sequencing the detection of live attenuated influenza vaccine (LAIV) viruses in one influenza B positive sample collected since week 40, from a child aged between 2 and 16 years of age.

Table 2. Number of influenza viruses characterised by genetic and antigenic analysis at the UKHSA Respiratory Virus Unit since week 34 of 2023

(Sub)type	Total number characterised	Genetic characterisation: genetic group	Genetic characterisation: number sequenced
A(H3N2)	18	3C.2a1b.2a.2a.3a.1	18
A(H1N1)pdm09	13	6B.1A.5a.2a	8
A(H1N1)pdm09	13	6B.1A.5a.2a.1	5
B/Victoria-lineage	1	V1A3a.2	1

Influenza antiviral susceptibility

Influenza positive samples are genome sequenced and screened for mutations in the virus neuraminidase (NA) and the cap-dependent endonuclease (PA) genes known to confer neuraminidase inhibitor or baloxavir resistance, respectively. The samples tested are routinely obtained for surveillance purposes, but diagnostic testing of patients suspected to be infected with antiviral-resistant virus is also performed.

Influenza virus sequences from samples collected between weeks 34 of 2023 and 43 of 23 have been analysed. Analysis of 18 A(H3N2) viruses found no viruses with known markers of resistance to neuraminidase inhibitors. Analysis of 11 A(H1N1)pdm09 by sequencing found one oseltamivir resistant virus with an H275Y amino acid substitution (99% H275Y). The sample was collected from an immune compromised adult who was known to have received oseltamivir treatment. Analysis of one influenza B NA sequence found no evidence of known markers of resistance to neuraminidase inhibitors.

No viruses with known markers of resistance to baloxavir marboxil were detected in 17 A(H3N2), 10 A(H1N1)pdm09 and one influenza B PA sequences analysed.

Table 3. Antiviral susceptibility of influenza positive samples tested at UKHSA-RVU

(Sub)type	Neuraminidase inhibitors: susceptible	Neuraminidase inhibitors: reduced susceptibility	Baloxavir: susceptible	Baloxavir: reduced susceptibility
A(H3N2)	18	0	17	0
A(H1N1)pdm09	10	1	10	0
B/Victoria-lineage	1	0	1	0

Community surveillance

Acute respiratory infection incidents (ARI)

Here we present data on ARI incidents in different settings that are reported to UKHSA Health Protection Teams (HPTs).

There were 53 new ARI incidents reported in week 43 in England:

- there were 41 incidents reported from care homes, where 8 had at least one linked case that tested positive for SARS-CoV-2, and one tested positive for parainfluenza
- there were 11 incidents reported from hospitals, where one had at least one linked case that tested positive for SARS-CoV-2
- there were no incidents reported from educational settings
- there was one incident reported from other settings that had at least one linked case that tested positive for Adenovirus

Figure 14: Number of ARI incidents by setting, England




Figure 15: Number of ARI incidents in all settings by virus type, England




Figure 16: Number of ARI incidents in care homes by virus type, England





Figure 17: Number of ARI incidents in educational settings by virus type, England




Google search queries

This is a web-based syndromic surveillance system which uses daily search query frequency statistics obtained from the Google Health Trends API (Application Programming Interface). This model focuses on search queries about COVID-19 symptoms as well as generic queries about 'coronavirus' (for example 'COVID-19'). The search query frequency time series is weighted based on symptom frequency as reported in other data sources. Frequency of searches for symptoms is compared with a baseline calculated from historical daily data. [Further information on this model](#) is available online.

During week 43, the overall and media-debiasing weighted Google search scores remained stable compared to the previous week (Figure 18).

Figure 18: Normalised Google search score for COVID-19 symptoms, with weighted score for media-debiasing and historical trend, England




Flu Detector

FluDetector is a web-based model which assesses internet-based search queries for influenza-like illness (ILI) in the general population.

Daily ILI rate estimates are based on uniformly averaged search query frequencies for a week-long period (including the current day and the 6 days before it).

For week 43, the daily ILI rate was low and below the baseline threshold of 10.25 per 100,000 for the 2023 to 2024 season (Figure 19).

Figure 19: Daily estimated ILI Google search query rates per 100,000 population, England




Syndromic surveillance

During week 43, NHS 111 calls for cold or flu increased nationally and were below seasonally expected level and calls for cough increased, mostly in children under 1 year old and in children between 1 and 4 years old. GP in hours consultation rates for ILI remained stable and similar to seasonally expected levels. ED for ARI continued to increase nationally and particularly in children aged under 5 years old (Figure 20). ED attendances for ILI remained stable nationally (Figure 21). ED attendances for acute bronchiolitis continued to increase nationally and particularly in children aged under 5 years old (Figure 22). ED for covid-19-like illness continued to decrease nationally and across all age groups.

For further information on syndromic surveillance please see the [Syndromic Surveillance: weekly summaries](#).

Figure 20: Daily ED attendances for acute respiratory infection, England (a) nationally, (b) by age group

(a)



(b)





Figure 21: Daily ED attendances for influenza-like illness, England (a) nationally, (b) by age group

(a)



(b)






Figure 22: Daily ED attendances for acute bronchiolitis, England (a) nationally, (b) by age group*

(a)



(b)




Please note, there has been no update in week 14 for acute bronchiolitis syndromic surveillance.

Primary care surveillance

RCGP Clinical Indicators (England)

The weekly ILI consultation rate through the Royal College of General Practitioners (RCGP) surveillance decreased slightly to 3.2 per 100,000 registered population in participating GP practices in week 43 compared to 3.5 per 100,000 in the previous week. This is within baseline activity levels (less than 10.25 per 100,000) (Figure 23). By age group, the highest rates were seen those aged under 1 years old (5.7 per 100,000) followed by adults aged between 15 and 44 years of age (3.8 per 100,000). The lower respiratory tract infections (LRTI) consultation remained stable at 77.9 per 100,000 in week 43 compared to 74.5 per 100,000 in the previous week.

Figure 23: RCGP ILI consultation rates, all ages, England




Moving Epidemic Method (MEM) thresholds are based on data from the 2015 to 2016 season to the 2022 to 2023 season. Please note the 2020 to 2021 and 2021 to 2022 seasons have been removed due to low activity throughout these seasons.

RCGP sentinel swabbing scheme in England

Based on the date samples were received in the reference laboratory, in week 43 2023 (week commencing 29 October 2023) 478 samples were tested through the GP sentinel swabbing scheme in England, of which 102 samples tested positive (Figure 24). Among all positive samples, 59.1% were positive for rhinovirus, 15.5% for RSV, 12.7% for SARS-CoV-2, 6.4% for hMPV, 2.7% for influenza, 2.7% for adenovirus and 0.9% for other coronavirus (Figure 25).

Based on the date samples were taken, positivity for SARS-CoV-2 was 6.3%, positivity for RSV was 7.3% and positivity for influenza was 0.0% in week 43 (Figure 26). Data for the most recent week will be updated retrospectively.


Figure 24: Number of samples tested for SARS-CoV-2, influenza, and other respiratory viruses in England by week, GP sentinel swabbing



Unknown category corresponds to samples with no result yet.


Source: RCGP Research and Surveillance Centre sentinel primary care practices ([RCGP Virology Dashboard](#))

Figure 25: Proportion of detections of SARS-CoV-2, influenza, and other respiratory viral strains amongst virologically positive respiratory surveillance samples in England by week, GP sentinel swabbing scheme



Source: RCGP Research and Surveillance Centre sentinel primary care practices ([RCGP Virology Dashboard](#))

Figure 26: Weekly positivity (%) for COVID-19, influenza and RSV in England, GP sentinel swabbing



Secondary care surveillance


Influenza, SARI Watch

Surveillance of influenza hospitalisations to all levels of care is based on data from a small sentinel network of acute NHS trusts in England. Surveillance of admissions to ICU or HDU for influenza is mandatory with data required from all acute NHS trusts in England. Please note that the SARI-Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020. The population denominator reflects changes in trust reconfiguration, hospital admission activity and population estimates.

In week 43 (ending 29 October 2023), the overall weekly hospital admission rate for influenza remained low at 0.22 per 100,000 compared to 0.11 per 100,000 in the previous week. The rate in the latest week remained at baseline activity levels. By age group, the highest hospital admission rate was in those aged 85 years and over. There were 18 new hospital admissions for influenza (11 influenza A(not subtyped), 2 influenza A(H1N1)pdm09, 2 influenza B and 3 influenza A(H3N2)).

In week 43, the overall ICU or HDU rate for influenza remained low at 0.02 per 100,000 compared to 0.01 per 100,000 in the previous week. The rate in the latest week remained at baseline activity levels. There were 7 new case reports of an ICU or HDU admission for influenza in week 43 (one influenza A(H1N1)pdm09, 4 influenza A(not subtyped) and 2 influenza B).

Figure 27: Weekly overall influenza hospital admission rates per 100,000 trust catchment population with MEM thresholds, reported through SARI Watch, England




MEM thresholds are based on data from the 2015 to 2016 to the 2022 to 2023 seasons.

Please note the 2020-21 and 2021-22 seasons have been removed due to low activity throughout these seasons.

Influenza hospital admission rate based on 19 sentinel NHS trusts for week 43.


SARI Watch data is provisional and subject to retrospective updates.

Figure 28: Weekly influenza hospital admissions by influenza type, reported through SARI Watch, England




Number of influenza hospital admissions based on sentinel NHS trusts.

Figure 29: Weekly hospital admission rate by UKHSA region for new influenza reported through SARI Watch*



Rates in some regions may not include all influenza surveillance sentinel sites from week to week. Please note the highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.

Figure 30: Weekly hospital admission rate by age group for new influenza reported through SARI Watch - a) fixed y-axis, b) adjusted y-axis



Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.





Figure 31: Weekly overall influenza ICU or HDU admission rates per 100,000 trust catchment population with MEM thresholds, reported through SARI Watch, England



MEM thresholds are based on data from the 2015 to 2016 to the 2022 to 2023 seasons. Please note the 2020 to 2021 and 2021 to 2022 seasons have been removed due to low activity throughout these seasons.

Influenza ICU or HDU admission rate based on 95 NHS trusts for week 43.

SARI Watch data is provisional and subject to retrospective updates.

Figure 32: Weekly influenza ICU or HDU admissions by influenza type, reported through SARI Watch, England






Figure 33: Weekly ICU or HDU admission rate by UKHSA region for new influenza, reported through SARI Watch




Please note the highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.

Figure 34: Weekly ICU or HDU admission rate by age group for new influenza cases, reported through SARI Watch - a) fixed y-axis, b) adjusted y-axis



Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.




COVID-19, SARI Watch

Surveillance of COVID-19 hospitalisations to all levels of care and surveillance of admissions to ICU or HDU for COVID-19 are both mandatory with data required from all acute NHS trusts in England. Please note that the SARI-Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020. The population denominator reflects changes in trust reconfiguration, hospital admission activity and population estimates.

In week 43 (ending 29 October 2023), the overall weekly hospital admission rate for COVID-19 decreased to 4.04 per 100,000 compared to 4.57 per 100,000 in the previous week. By UKHSA region, the highest hospital admission rate for COVID-19 was observed in the West Midlands. By age group, the highest hospital admission rate for COVID-19 continues to be in those aged 85 years old and over.

In week 43 (ending 29 October 2023), the overall weekly ICU or HDU admission rate for COVID-19 remained stable at 0.14 per 100,000, compared to 0.16 per 100,000 in the previous week. Note that ICU or HDU admission rates may represent a lag from admission to hospital to an ICU or HDU ward. The ICU or HDU admission rate for COVID-19 by UKHSA region or by age group fluctuated at low levels in week 43 due to low underlying numbers.


Figure 35: Weekly overall COVID-19 hospital admission rates per 100,000 trust catchment population, reported through SARI Watch, England



COVID-19 hospital admission rate based on 86 NHS trusts for week 43.

SARI Watch data is provisional and subject to retrospective updates.


Figure 36: Weekly hospital admission rate by UKHSA region for new COVID-19 positive cases, reported through SARI Watch*



Please note the highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.

Figure 37: Weekly hospital admission rate by age group for new COVID-19 positive cases reported through SARI Watch - a) fixed y-axis, b) adjusted y-axis

a)



Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.

b)






Figure 38: Weekly overall COVID-19 ICU or HDU admission rates per 100,000 trust catchment population, reported through SARI Watch, England



COVID-19 ICU or HDU admission rate based on 78 NHS trusts for week 43.


SARI Watch data is provisional and subject to retrospective updates.

Figure 39: Weekly ICU or HDU admission rate by UKHSA region for new COVID-19 positive cases reported through SARI Watch




Please note the highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.

Figure 40: Weekly ICU or HDU admission rate by age group for new COVID-19 positive cases reported through SARI Watch - a) fixed y-axis, b) adjusted y-axis




Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.



ECMO, SARI Watch

There was one new extra corporeal membrane oxygenation (ECMO) admission reported in week 43 from the 7 Severe Respiratory Failure (SRF) centres in the UK. The admission was not related to acute respiratory infection.

Figure 41: Laboratory confirmed ECMO admissions in adults (COVID-19, influenza and non-COVID-19 confirmed) to Severe Respiratory Failure centres in the UK




SARI Watch data is provisional and subject to retrospective updates.

RSV admissions, SARI Watch

Data on hospitalisations, including ICU or HDU admissions, with respiratory syncytial virus (RSV) are shown below. RSV SARI Watch surveillance is sentinel. Please note that the SARI-Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020. The population denominator reflects changes in trust reconfiguration, hospital admission activity and population estimates.

In week 43, the overall hospital admission rate for RSV increased to 2.27 per 100,000 compared to 1.23 per 100,000 in the previous week. The highest rate was seen in the under 5 year olds at 30.3 per 100,000, which increased from 18.8 per 100,000 in the previous week.

Figure 42: Weekly overall hospital admission rates (including ICU or HDU) of RSV positive cases per 100,000 population reported through SARI Watch, England



Please note that rates are based on the number of hospitalised cases divided by the Trust catchment population, multiplied by 100,000.

Figure 43: Weekly count hospital admissions of RSV positive cases reported through SARI Watch sentinel surveillance by level of care, England






Figure 44: Weekly hospitalisation (including ICU or HDU) admission rates by age group for new RSV cases reported through SARI Watch, England - a) fixed y-axis, b) adjusted y-axis

a)



Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.

b)



SARI Watch data is provisional.

Mortality surveillance

COVID-19 deaths

For further information on COVID-19 related deaths in England please see the [COVID-19 dashboard for death](#).

Daily excess all-cause mortality (England)

For further information on excess all-cause mortality in England please see the [Fingertips excess mortality in England report](#), which uses Office for National Statistics (ONS) death registration data and the [all-cause mortality surveillance report](#), which uses the European mortality monitoring (EuroMOMO) model to identify weeks with higher than expected mortality.

Influenza vaccination


Influenza vaccine uptake in GP patients

Weekly vaccine coverage data is provisional.

Up to week 43 of 2023, in 39.4% of GP practices reporting weekly to ImmForm for the main collection, the provisional proportion of people in England who had received the 2023 to 2024 influenza vaccine in targeted groups was as follows:

- 29.4% in under 65 years in a clinical risk group
- 23.0% in all pregnant women
- 68.5% in all those aged 65 years and over

Figure 45: Cumulative weekly influenza vaccine uptake by target group in England




* = excluding pregnant women without other risk factors ** = Healthy and At Risk

In 2023 to 2024, all 2 and 3 year olds continue to be eligible for influenza vaccination through their GPs. Up to week 43 of 2023, in 94.7% of GP practices reporting weekly to ImmForm for the childhood collection, the provisional proportion of children in England who had received the 2023 to 2024 influenza vaccine in targeted groups was as follows:

- 30.7% in all 2 year olds
- 29.7% in all 3 year olds

Figure 46: Cumulative weekly influenza vaccine uptake in 2 and 3 year olds, in England



COVID-19 vaccination

COVID-19 vaccine uptake in England

COVID-19 vaccinations began in England on 8 December 2020 during week 50 2020 (week ending 13 December 2020). Cumulative data up to week 44 2023 (week ending 29 October 2023) was extracted from the National Immunisation Management Service (NIMS). The data presented this week is the provisional proportion of living people resident in England who had received COVID-19 vaccinations. Individuals vaccinated in England who have a registered address outside of England or where their address, age, or sex is unknown have been excluded. Due to changes in GP practice lists, in order to include newly registered patients and remove those who are no longer resident, there will be slight variation to the figures to reflect those who are currently resident in England.

Age is calculated as age on 31 March 2024. From 23 October, data is extracted on a Monday with data capped to the previous Sunday. This change from Tuesday data extraction means that because of data lags, reported coverage for the most recent week is marginally lower than if data was extracted on Tuesday. This change has been implemented to help ensure timely reporting. All backing data is updated each week going back to the start of the programme.

Data is provisional and subject to change following further validation checks. There are significant changes being undertaken in the data feeds that provide these statistics. It is therefore necessary to report the autumn campaign on a fixed denominator, the population as at 31 August 2023. Any changes to historic figures will be reflected in the most recent publication. Please note that numbers published by UKHSA are for public health surveillance purposes only.

Autumn 2023 Campaign

Immunity derived from vaccination declines over time, Joint Committee on Vaccination and Immunisation (JCVI) has recommended an autumn 2023 campaign with the primary objective to boost immunity in those at higher risk from COVID-19 and thereby optimise protection against severe COVID-19, specifically hospitalisation and death in time for winter 2023 to 2024.

The autumn 2023 data reported below covers any dose administered from the 1 September 2024 provided there is at least 20 days from the previous dose. Eligible groups for the autumn campaign are defined in the COVID-19 healthcare guidance [Green Book](#).

Table 4 presents coverage as measured against the total population and includes people who are not yet due to have their Autumn 2023 booster, specifically those turning 65 years of age by the 31 March 2024. It is important that unvaccinated individuals, especially vulnerable adults, receive a primary course of vaccination, irrespective of whether individuals have had previous infection. To understand the data in the context of vaccine waning across the whole COVID-19 programme, we present Table 5 which shows how recently a person who is living and resident

in England has been vaccinated either through the primary vaccination campaign or a subsequent booster campaign.


By the end of week 44 2023 (week ending 29 October 2023), 55.1% (6,146,673 out of 11,164,326) of all people aged over 65 years old who are living and resident in England who had been vaccinated with an autumn 2023 booster dose since 1 September 2023, Table 4 and Figure 47.

Table 4. Provisional cumulative people vaccinated by age with a dose of COVID-19 vaccine from the 1 September 2023 as part of the autumn 2023 campaign in England

National	People in NIMS cohort who are living and resident in England	Vaccinated since 1 September 2023 *	Percentage vaccine uptake
Over 80	3,010,182	1,985,720	66.0
75 to under 80	2,458,682	1,634,867	66.5
70 to under 74	2,672,292	1,621,058	60.7
65 to under 70	3,023,170	1,565,485	51.8
Aged 65 and over	11,164,326	6,807,130	61.0

*Autumn 2023 booster defined as any dose of vaccine given after 1 September 2023, provided there is an interval of at least 20 days since any previous dose.

Figure 47. Cumulative weekly COVID-19 vaccine uptake in those who are living and resident in England vaccinated with an Autumn 2023 dose since 1 September 2023.



Please note that this graph shows data for the autumn 2022 campaign and does not correspond to the date axis but is aligned to the current autumn 2023 campaign to allow comparison of the rate of uptake in both campaigns.

Proportion of people vaccinated by time since last vaccination

Table 5. Provisional cumulative people vaccinated with any dose of COVID-19 vaccine in the last 3 months, 3 to 6 months and vaccinated more than 6 months ago

National	People in NIMS cohort who are living and resident in England	Vaccinated in the last 3 months (84 days)		Vaccinated 3 to 6 months ago (85 to 168 days)		Vaccinated 6 months ago (169 or more days)	
		Numbers vaccinated	Percentage vaccinated	Numbers vaccinated	Percentage vaccinated	Numbers vaccinated	Percentage vaccinated
Over 80	3,010,182	1,985,734	66.0	208,567	6.9	712,837	23.7
75 to under 80	2,458,682	1,634,887	66.5	168,114	6.8	565,703	23.0
70 to under 75	2,672,292	1,621,095	60.7	19,166	0.7	892,513	33.4
65 to under 70	3,023,170	1,565,533	51.8	16,093	0.5	1,231,219	40.7
60 to under 65	3,691,023	849,365	23.0	17,784	0.5	2,505,688	67.9
55 to under 60	4,133,235	598,152	14.5	15,962	0.4	3,081,070	74.5
50 to under 55	4,127,778	425,285	10.3	11,915	0.3	3,133,606	75.9
45 to under 50	3,873,067	262,955	6.8	7,626	0.2	2,877,687	74.3
40 to under 45	4,410,433	207,564	4.7	6,168	0.1	3,158,343	71.6
35 to under 40	4,711,499	166,429	3.5	4,862	0.1	3,218,954	68.3
30 to under 35	4,788,980	133,367	2.8	3,999	0.1	3,164,846	66.1
25 to under 30	4,416,848	91,901	2.1	3,156	0.1	2,916,196	66.0
20 to under 25	3,787,791	57,797	1.5	2,369	0.1	2,622,391	69.2
18 to under 20	1,402,413	13,716	1.0	1,448	0.1	939,655	67.0
16 to under 18	1,430,176	7,726	0.5	1,466	0.1	864,238	60.4
12 to under 16	2,994,199	12,135	0.4	3,792	0.1	1,242,619	41.5
5 to under 12	4,998,730	4,891	0.1	5,028	0.1	464,283	9.3

Table 5 is presented to provide an overview of how recently a person has been vaccinated either through the primary vaccination campaign or subsequent booster campaigns. This helps us understand the data in the context of vaccine waning across the whole COVID-19 programme. Breakdowns by Ethnicity, and IMD, for those aged 65 and over can be found in the backing tables.

A regional breakdown of the ethnicity data is available in the [accompanying data file](#) for this report.

For COVID-19 data on the real-world effectiveness of the COVID-19 vaccines, and on COVID-19 vaccination in pregnancy, please see [the COVID-19 vaccine surveillance reports](#).

For COVID-19 management information on the number of COVID-19 vaccinations provided by the NHS in England, please see the [COVID-19 vaccinations](#) webpage.

For UK COVID-19 daily vaccination figures and definitions, please see the [Vaccinations' section of the UK COVID-19 dashboard](#).

The population coverage data representing the evergreen offer of doses 1, 2, and 3 has changed little in recent months and are no longer presented in both the UKHSA weekly flu and COVID-19 surveillance reports and in the UK COVID-19 Dashboard. Both the UKHSA weekly flu and COVID-19 surveillance reports and in the UK COVID-19 Dashboard now highlight data on the most recent vaccination campaign in those at higher risk from COVID-19 as immunity derived from vaccination declines over time. The overall vaccine uptake in the living and resident population for those with at least dose 1, 2 and 3 doses is still available within the backing tables for this section and in the dashboard APIs.

International update

Global COVID-19 update

For further information on the global COVID-19 situation please see the [World Health Organization \(WHO\) COVID-19 situation reports](#).

Global influenza update

For further information on the global influenza situation please see the [World Health Organization \(WHO\) Influenza update](#).

Influenza in Europe

For further information on influenza in Europe please see the [European Respiratory Virus Surveillance Summary weekly update](#).

Influenza in North America

For further information on influenza in the United States of America please see the [Centre for Disease Control weekly influenza surveillance report](#). For further information on influenza in Canada please see the [Public Health Agency weekly influenza report](#).

Influenza in Australia

For further information on influenza in Australia, please see the [Australian Influenza Surveillance Report and Activity Updates](#).

Other respiratory viruses

Avian influenza and other zoonotic influenza

For further information, please see the [Latest WHO update on 14 July 2023](#) and the [Latest UKHSA avian influenza technical briefing 14 July 2023](#)

Middle East respiratory syndrome coronavirus (MERS-CoV)

For further information please see the [WHO Disease Outbreak News Reports](#) and the [WHO publishes monthly updates](#).

[Further information on management and guidance of possible cases](#) is available online. The latest [ECDC MERS-CoV risk assessment](#) highlights that risk of widespread transmission of MERS-CoV remains very low.

Related links

[Previous national COVID-19 reports](#)

[Previous weekly influenza reports](#)

[Annual influenza reports](#)

[COVID-19 vaccine surveillance reports](#)

[Previous COVID-19 vaccine surveillance reports](#)

[Public Health England \(PHE\) monitoring of the effectiveness of COVID-19 vaccination](#)

[Investigation of SARS-CoV-2 variants of concern: technical briefings](#)

[Sources of surveillance data for influenza, COVID-19 and other respiratory viruses](#)

[RCGP Virology Dashboard](#)

UKHSA has delegated authority, on behalf of the Secretary of State, to process Patient Confidential Data under Regulation 3 The Health Service (Control of Patient Information) Regulations 2002

Regulation 3 makes provision for the processing of patient information for the recognition, control and prevention of communicable disease and other risks to public health.

About the UK Health Security Agency

UKHSA is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation health secure.

The [UK Health Security Agency](#) is an executive agency, sponsored by the [Department of Health and Social Care](#).

© Crown copyright 2023

Prepared by: Immunisation and Vaccine Preventable Diseases Division
For queries relating to this document, please contact: Enquiries@ukhsa.gov.uk

Published: 2 November 2023

Publishing reference: GOV-15693



You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](#). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.



UKHSA supports the UN
Sustainable Development Goals

